Patent ID: 11865149
Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  C  G

Claim 5:
6. A method for treating cancer in a mammal, wherein said method comprises:
(a) identifying said mammal as having cancer cells that lack:
(1) low expression of at least 50 percent of the genes selected from the Gene Set 1 group consisting of IFI27, IFI27L1, IFI30, IFI6, IFI35, IFI16, IFI44, IFIT3, IFIT2, MIT1, IFIT1B, IFIT5, IFITM3, TRIM14, TRIM69, TRIM21, TRIM25, TRIM39, TRIMS, TRIM26, TRIM47, OASL, OAS2 and MX1, as compared to expression by healthy control cells of the same tissue type as the cancer cells;
(2) low expression of at least 50 percent of the genes selected from the Gene Set 2 group consisting of DDX60, DDX60L, DHX58, DDX58, ISG15, IFIH1, CD14, LBP, TLR4, MYD88, TOLLIP, TLR3, TLR5, TLR6, TLR9, TICAM1, IRF7, IRF5, MAPK11, APK12, MAPK8, RIPK1, IKBKG and NFKBIA, as compared to expression by healthy control cells of the same tissue type as the cancer cells;
(3) low expression of at least 50 percent of the genes selected from the Gene Set 3 group consisting of IFNAR1, IFNAR2, IFNGD1, IRF1, JAK1, STAT1, STAT2, STAT3, STAT5A, IRF9, PIK3R2, PIK3CG, AKT1, AKT2, AKT3 and MTOR, as compared to expression by healthy control cells of the same tissue type as the cancer cells; and
(4) low expression of at least 50 percent of the genes selected from the Gene Set 4 group consisting of PSMB8, PSMB9, PSMB10, PSME1, PSME2, TAP1, TAP2, TAPBP, TAPBPL, ERAP1, ERAP2, CALR, PDIA3, HLA-A, HLA-B, HLA-C, BTN3A1, BTN3A2, BTN3A3 and B2M, as compared to expression by healthy control cells of the same tissue type as the cancer cells; and
(b) administering an oncolytic virus to said mammal at a dose of 1×109 TCID50 or greater at least once every two to four weeks for a total of at least two administration to induce an immune response against said cancer, wherein the number of cancer cells within the mammal is reduced.